Published in PLoS One on October 23, 2013
Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers. Genome Med (2014) 0.81
TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer (2016) 0.79
Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis. Cancer Cell Int (2014) 0.79
Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study. Mol Cancer Ther (2016) 0.75
Metastasis as a therapeutic target in prostate cancer: a conceptual framework. Am J Clin Exp Urol (2014) 0.75
A Novel Role of E-Cadherin-Based Adherens Junctions in Neoplastic Cell Dissemination. PLoS One (2015) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev (2006) 7.92
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol (2003) 7.89
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 6.52
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol (2004) 4.16
Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol (2000) 3.53
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol (2001) 3.32
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 2.89
CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 2.28
Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem (1994) 2.22
New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta (2011) 2.22
CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J (2002) 2.05
Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood (2008) 1.98
CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol (1998) 1.93
Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell (2000) 1.90
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J (1997) 1.85
Matrix metalloproteinases in human melanoma. J Invest Dermatol (2000) 1.84
Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol (1996) 1.84
Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci U S A (1980) 1.65
Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem (2000) 1.59
Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell (2001) 1.51
Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci (2013) 1.47
Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol (1999) 1.46
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis (1999) 1.46
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem (2010) 1.31
Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma (1993) 1.27
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia (2008) 1.25
Role of cadherins in the transendothelial migration of melanoma cells in culture. Cell Motil Cytoskeleton (1997) 1.25
Membrane associated matrix metalloproteinases in metastasis. Bioessays (1999) 1.24
Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res (1994) 1.23
Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov (2009) 1.21
Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech (1998) 1.20
Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol (2010) 1.18
Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem (1999) 1.13
Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J Biol Chem (2000) 1.13
Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol Life Sci (2000) 1.13
The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J (1993) 1.08
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol (1994) 1.08
Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer (2005) 1.05
Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene (2006) 1.05
Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol Biol Cell (2008) 1.05
Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood (1997) 1.04
Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett (1998) 1.03
The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J Mol Biol (2008) 1.02
The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation. J Biol Chem (1998) 1.02
Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene (1998) 1.00
Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis (1995) 0.99
Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One (2012) 0.97
Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem (2009) 0.96
Furin-independent pathway of membrane type 1-matrix metalloproteinase activation in rabbit dermal fibroblasts. J Biol Chem (1999) 0.90
A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis (2007) 0.89
Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS One (2012) 0.89
Cell shape changes and cytoskeleton reorganization during transendothelial migration of human melanoma cells. Cell Tissue Res (1998) 0.88
Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. J Biol Chem (2003) 0.87
Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A. Am J Pathol (2012) 0.86
Intradomain cleavage of inhibitory prodomain is essential to protumorigenic function of membrane type-1 matrix metalloproteinase (MT1-MMP) in vivo. J Biol Chem (2011) 0.84
Platelet-endothelial cell adhesion molecule-1 (CD31) redistributes from the endothelial junction and is not required for the transendothelial migration of melanoma cells. Clin Exp Metastasis (2000) 0.84
The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7. BMC Cancer (2011) 0.84
Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. Clin Exp Metastasis (2008) 0.81
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer (2008) 4.43
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev (2011) 2.97
Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet (2004) 2.96
Animal models for medical countermeasures to radiation exposure. Radiat Res (2010) 2.83
The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.71
RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev (2005) 2.59
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33
iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (2012) 2.14
Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol (2003) 2.12
Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation (2007) 2.03
Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science (2004) 2.03
Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res (2010) 1.97
The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis (2003) 1.94
The tumor microenvironment and metastatic disease. Clin Exp Metastasis (2008) 1.91
Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. Int J Radiat Oncol Biol Phys (2007) 1.77
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res (2005) 1.77
Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest (2005) 1.76
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest (2010) 1.75
Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity (2012) 1.75
Integration of single and multicellular wound responses. Curr Biol (2009) 1.62
ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci (2010) 1.49
pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol (2004) 1.45
Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol (2006) 1.45
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res (2012) 1.41
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res (2007) 1.40
Partial volume rat lung irradiation: the protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic. Radiother Oncol (2006) 1.39
Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res (2004) 1.38
Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction (2007) 1.37
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology (2008) 1.36
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
Partial volume rat lung irradiation: temporal fluctuations of in-field and out-of-field DNA damage and inflammatory cytokines following irradiation. Int J Radiat Biol (2005) 1.35
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J (2008) 1.32
Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology (2005) 1.31
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30
Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol (2003) 1.28
The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci (2008) 1.28
Rehabilitation and the single cell. Curr Opin Cell Biol (2006) 1.26
Clipping, shedding and RIPping keep immunity on cue. Trends Immunol (2008) 1.20
Hypoxia and metastasis. Clin Cancer Res (2007) 1.20
Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene (2003) 1.20
Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev (2004) 1.18
Control of local Rho GTPase crosstalk by Abr. Curr Biol (2011) 1.17
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res (2010) 1.17
Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum (2007) 1.16
Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci (2012) 1.13
The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro. Photochem Photobiol Sci (2008) 1.12
Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost (2005) 1.12
Hypoxia and metastasis in breast cancer. Breast Dis (2007) 1.11
Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development (2013) 1.11
Mitigation of radiation-induced lung injury by genistein and EUK-207. Int J Radiat Biol (2011) 1.10
Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem (2009) 1.10
Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am J Pathol (2009) 1.10
Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest (2007) 1.08
Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol (2005) 1.08
Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer (2008) 1.07
Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.07
Genistein can mitigate the effect of radiation on rat lung tissue. Radiat Res (2010) 1.06
A null mutation for tissue inhibitor of metalloproteinases-3 (Timp-3) impairs murine bronchiole branching morphogenesis. Dev Biol (2003) 1.04
Spontaneous resolution of coronary artery pseudoaneurysm consequent to percutaneous intervention with paclitaxel-eluting stent. Tex Heart Inst J (2008) 1.04
Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem (2011) 1.03
Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol (2006) 1.03
Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology (2010) 1.03
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther (2008) 1.03
Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res (2002) 1.02
Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res (2004) 1.02
Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem (2010) 1.02
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res (2004) 1.01
High-resolution in-vivo analysis of normal brain response to cranial irradiation. PLoS One (2012) 1.00
Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res (2008) 0.99
Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol (2005) 0.98
MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. PLoS One (2013) 0.98
Hypoxic activation of the PERK/eIF2α arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin Cancer Res (2013) 0.98
Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem (2003) 0.98
A fluorescent orthotopic model of metastatic cervical carcinoma. Clin Exp Metastasis (2004) 0.98
A functional connection between pRB and transforming growth factor beta in growth inhibition and mammary gland development. Mol Cell Biol (2009) 0.97
Effects of genistein following fractionated lung irradiation in mice. Radiother Oncol (2009) 0.97
TIMP-3 recruits quiescent hematopoietic stem cells into active cell cycle and expands multipotent progenitor pool. Blood (2010) 0.97
Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys (2002) 0.96
Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol (2008) 0.96
Cbl-3-deficient mice exhibit normal epithelial development. Mol Cell Biol (2003) 0.95
Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem (2005) 0.95
Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors. Lab Invest (2009) 0.95
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol (2008) 0.94
Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer (2009) 0.93
Effect of radiation and cell implantation on wound healing in a rat model. J Surg Oncol (2003) 0.92
Proteolytic factors in exosomes. Proteomics (2013) 0.90
Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. Cancer (2011) 0.90